(Q38676458)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

NK cells and cancer: you can teach innate cells new tricks (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Lewis L Lanier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

7-19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26694935%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2015.5

3 March 2020

exact match

0 references

cites work

The biology of innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Natural killer cell deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Up on the tightrope: natural killer cell activation and inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Effects of Peptide on NK cell-mediated MHC I recognition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Innate or adaptive immunity? The example of natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKG2D Receptor and Its Ligands in Host Defense

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Regulation of ligands for the NKG2D activating receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Natural cytotoxicity receptors and their ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Balancing natural killer cell activation through paired receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Accelerated tumor growth in mice deficient in DNAM-1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Properties of mouse and human IgG receptors and their contribution to disease models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Perforin and granzymes: function, dysfunction and human pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Regulation of perforin‐independent NK cell‐mediated cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Activation of NK cell cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Role of chemokines in the biology of natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A new immunodeficiency disorder in humans involving NK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Deficient Natural Killer Cell Activity in X-Linked Lymphoproliferative Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Role of NK cells in the control of metastatic spread and growth of tumor cells in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Surface markers of NK cells in peripheral blood of patients with cirrhosis and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Low natural-killer-cell activity in familial melanoma patients and their relatives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

New aspects of natural-killer-cell surveillance and therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Molecular definition of the identity and activation of natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKG2D ligands in tumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Soluble NKG2D ligands: prevalence, release, and functional impact.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Soluble MICA in malignant diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Effect of NKG2D ligand expression on host immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The wolf in sheep's clothing: Platelet-derived "pseudo self" impairs cancer cell "missing self" recognition by NK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Modulation of natural killer cell anti-tumor reactivity by platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Tumor growth impedes natural-killer-cell maturation in the bone marrow.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Interleukin-10 and the immune response against cancer: a counterpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression of ligands to NKp46 in benign and malignant melanocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKG2D function protects the host from tumor initiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Tumor immunoediting by NKp46.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Enhancement of NK cell antitumor responses using an oncolytic parvovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Prospects for TIM3-Targeted Antitumor Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Agonist antibodies to TNFR molecules that costimulate T and NK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cytokine-induced memory-like natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Toward the next generation of NK cell-based adoptive cancer immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cytokine treatment in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cytokine therapy reverses NK cell anergy in MHC-deficient tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Utilizing chimeric antigen receptors to direct natural killer cell activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Pluripotent stem cell-derived natural killer cells for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Are natural killer cells superior CAR drivers?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NKG2D CARs as cell therapy for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

NK cells lyse T regulatory cells that expand in response to an intracellular pathogen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2015.5

Natural killer cell activity and head and neck cancer: a clinical assessment

31 March 2020

1 reference

12 December 2020

Advantages and applications of CAR-expressing natural killer cells

1 reference

12 December 2020

Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1)

1 reference

12 December 2020

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

1 reference

12 December 2020

Autologous natural killer cell therapy for human recurrent malignant glioma.

1 reference

12 December 2020

Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).

1 reference

12 December 2020

Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice

1 reference

12 December 2020

Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells

1 reference

12 December 2020

Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells.

1 reference

12 December 2020

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.

1 reference

12 December 2020

Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer

1 reference

12 December 2020

Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells

1 reference

12 December 2020

NKG2D ligands as therapeutic targets

1 reference

12 December 2020

T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice

1 reference

12 December 2020

Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective

1 reference

12 December 2020

Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits

1 reference

12 December 2020

Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer

1 reference

12 December 2020

Human NK cell lytic granules and regulation of their exocytosis

1 reference

12 December 2020

Role of natural killer cells in cancer.

1 reference

12 December 2020